Biote Issues Full-Year 2026 Revenue Guidance Amid Recovery Efforts Following Product Recall

Biote (BTMD) has announced full-year 2026 revenue guidance exceeding $175 million, despite experiencing a 9.6% year-over-year decline in third-quarter revenue to $43.3 million. The company's recent financial contraction was primarily driven by a voluntary product recall in January 2026, which delayed new clinic onboarding and reduced clinical procedure volumes. To drive recovery, management is implementing data analytics to support underperforming clinics and standardizing medical training to improve practitioner retention. Additionally, the company is working to restore gross margins by ramping up production at its internal manufacturing facility, Xteria Health, which now supplies over 50% of shipped pellets, up from 30% in the second quarter.

By The Motley Fool Team · Motley Fool ·

Biote Issues Full-Year 2026 Revenue Guidance Amid Recovery Efforts Following Product Recall

Topics: data analytics earnings report healthcare management product recall revenue guidance

Read the full article at Motley Fool

More World news